REGULATORY

• First Two Homegrown COVID-19 Jabs Up for MHLW Panel Review on July 31
  July 31, 2023

• Japan Safety Panels Recognize 2nd Death Possibly Linked to COVID Vaccine
  July 31, 2023

• Japan to Buy 20 Million Doses of Pfizer COVID Jab, 5 Million from Moderna
  July 28, 2023

• Japan Likely to Slash Moderna Vaccine Purchase, Pfizer Single-Sourcing Plan Nixed
  July 28, 2023

• Chuikyo Medical Device Pricing Body Calls for Clearer Reimbursement Criteria for SaMDs
  July 27, 2023

• Chuikyo Wary of Abolishing Spillover Rule, Positive on Reviewing Market Expansion Re-Pricing
  July 27, 2023

• Chuikyo Divided Over Raising Premium Rates for Listed Products, Extending Evaluation Data
  July 27, 2023

• Japan OKs FY2024 Budget Ceilings, 520 Billion Yen for Social Security Cost Rise
  July 26, 2023

• MHLW Pharma Bureau Chief Eager to Do Everything on Regulation Panel’s Agenda
  July 25, 2023

• Label Expansions for Jakavi, Soliris in Line for Approval
  July 25, 2023

• Panel on Generic Industry to Boot Up July 31, Report Expected by Fall
  July 25, 2023

• Label Updated for ViiV’s 4 HIV Meds to Change Caution for Patients with Renal Dysfunctions
  July 24, 2023

• 93 Health Damages Reported for Temcell in Japan: October-March
  July 24, 2023

• Japan Embassy Granted First In-Person Visit to Detained Astellas Employee
  July 24, 2023

• Japan Might See COVID-19 Spike in Summer: Top Govt Spokesman
  July 24, 2023

• Tadayuki Mizutani Tapped as MHLW Director for Pharma Industry Promotion
  July 24, 2023

• Phase Out or Scrap Inflation Mitigation Measures: CEFP Members
  July 21, 2023

• Label Revisions Ordered for Xocova, Mounjaro to Add New ADR Risks
  July 21, 2023

• LDP Policy Panel OKs FY2024 Budget Guidelines, Social Security Wording Unchanged
  July 20, 2023

• Japan’s 1st Stelara, G-Lasta Biosimilars Nearing Finish Line
  July 18, 2023

ページ

• « 先頭
• ‹ Prev
• …
• 78
• 79
• 80
• 81
• 82
• 83
• 84
• 85
• 86
• …
• Next ›
• 最終 »